Algernon Health Inc. (CSE:AGN)

Canada flag Canada · Delayed Price · Currency is CAD
0.0850
0.00 (0.00%)
Oct 30, 2025, 3:53 PM EDT
Market Cap2.91M
Revenue (ttm)n/a
Net Income (ttm)-1.76M
Shares Out34.26M
EPS (ttm)-0.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,160
Average Volume26,723
Open0.0800
Previous Close0.0850
Day's Range0.0800 - 0.0850
52-Week Range0.0550 - 0.1225
Beta1.65
RSI67.39
Earnings DateNov 26, 2025

About Algernon Health

Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol AGN
Full Company Profile

Financial Performance

Financial Statements

News

CSE Bulletin: Name Change - Algernon Pharmaceuticals Inc. (AGN)

Toronto, Ontario--(Newsfile Corp. - Le 16 octobre/October 2025) - Algernon Pharmaceuticals Inc. has announced a name change to Algernon Health Inc. Shares will begin trading under the new name and wit...

14 days ago - Newsfile Corp

Algernon Pharmaceuticals changes name to Algernon Health

Algernon Pharmaceuticals (AGNPF) announced name change to Algernon Health.

16 days ago - Seeking Alpha

Algernon Pharmaceuticals Completes Name Change to Algernon Health

VANCOUVER, British Columbia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company an...

16 days ago - GlobeNewsWire

Catalyst MedTech Launches "Connect" Program to Expand Access to Advanced Imaging; Announces Initial Partnership with Algernon Pharmaceuticals

PITTSBURGH , Oct. 7, 2025 /PRNewswire/ -- Catalyst MedTech today announced the launch of its new Connect program, an initiative that brings together collaborators seeking to advance patient care with ...

23 days ago - PRNewsWire

Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer's Detection

VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...

5 weeks ago - GlobeNewsWire

Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer's Detection

VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...

5 weeks ago - Benzinga

Algernon Announces Preferred Share Class Approved at Annual and Special Meeting

VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...

5 weeks ago - GlobeNewsWire

Algernon Pharmaceuticals Announces Name Change to Algernon Health

VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...

2 months ago - GlobeNewsWire

Algernon Announces Closing of the Private Placement Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

3 months ago - GlobeNewsWire

Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

4 months ago - GlobeNewsWire

Algernon Announces $1M Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “...

5 months ago - GlobeNewsWire

Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinica...

5 months ago - GlobeNewsWire

Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology

VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinica...

6 months ago - GlobeNewsWire

Algernon Announces Warrant Extension

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

6 months ago - GlobeNewsWire

Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease

VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharm...

7 months ago - GlobeNewsWire

Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing

VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pha...

8 months ago - GlobeNewsWire

Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study

VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage phar...

9 months ago - GlobeNewsWire

Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare's USD $170K Equity Investment

VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage phar...

9 months ago - GlobeNewsWire

Algernon CEO Discusses Ifenprodil Sale to Seyltx and DMT as a Treatment for Stroke and TBI

Christopher Moreau, CEO of Algernon Pharmaceuticals, discusses the company’s sale of Ifenprodil to Seyltx, and their current focus on DMT as a treatment for stroke and traumatic brain injury.

11 months ago - BNN Bloomberg

How Algernon Pharmaceuticals is Unlocking Sub-Psychedelic DMT for Stroke and TBI Treatment

In response to this global need for more universal and broadly deliverable, frontline treatments, Algernon Pharmaceuticals Inc. (CSE: AGN | OTCQB: AGNPF | FSE: AGW0) (AGN Pharma), through its wholly-o...

11 months ago - BNN Bloomberg

Algernon Announces Warrant Extension

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR  DISSEMINATION IN THE UNITED STATES

1 year ago - GlobeNewsWire

Algernon Pharmaceuticals Announces Closing of Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKF...

1 year ago - GlobeNewsWire

Algernon Pharmaceuticals Announces Increase to Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKF...

1 year ago - GlobeNewsWire

Algernon Pharmaceuticals Announces Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKF...

1 year ago - GlobeNewsWire

Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services

VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharm...

1 year ago - GlobeNewsWire